Diane’s farewell message
After 52 years at WAMU, Diane Rehm says goodbye.
The Vioxx recall is just the latest of several episodes this year that have prompted criticism of the FDA and Senate hearings. A panel talks about the drug approval process, post-marketing safety surveillance, and how the agency’s work affects Americans’ health and safety.
Guests
- Marc Kaufman Reporter on the national desk of "The Washington Post"
- Dr. Jerry Avorn Author of "Powerful Medicines," professor of medicine at Harvard Medical School, and chief of the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women's Hospital in Boston
- Alan Goldhammer, PhD Associate vice president for regulatory affairs at the Pharmaceutical Research and Manufacturers of America (PhRMA)
- Sen. Charles Grassley (R-Iowa), ranking member of the Senate Finance Committee
- Dr. Sandra Kweder Deputy director of the FDA's Office of New Drugs
Most Recent Shows
Reflections on 100 days of the Trump administration
Diane takes the mic one last time at WAMU. She talks to Susan Page of USA Today about Trump’s first hundred days – and what they say about the next hundred.
Rep. Jamie Raskin on countering “MAGA chaos”
Maryland Congressman Jamie Raskin was first elected to the House in 2016, just as Donald Trump ascended to the presidency for the first time. Since then, few Democrats have worked as…
How deportations ignited a clash between the White House and the courts
Can the courts act as a check on the Trump administration’s power? CNN chief Supreme Court analyst Joan Biskupic on how the clash over deportations is testing the judiciary.